8-K: MIRA Pharmaceuticals Achieves Key Safety Milestone for Ketamir-2, Eyes IND Submission

MIRA Pharmaceuticals has successfully completed preclinical safety studies for its novel oral ketamine analog, Ketamir-2, with no adverse findings, paving the way for an Investigational New Drug (IND) application submission by the end of 2024.

Summary

• MIRA Pharmaceuticals has completed its Good Laboratory Practice (GLP) preclinical safety program for Ketamir-2, a novel oral ketamine analog.
• The studies showed no adverse effects across cardiovascular, central nervous system (CNS), and respiratory systems.
• Toxicology studies in dogs showed Ketamir-2 was well-tolerated at daily doses up to 200 mg/kg.
• The Ames test confirmed that Ketamir-2 is non-mutagenic.
• The company plans to submit an Investigational New Drug (IND) application by the end of 2024.
• Phase I clinical trials are scheduled to begin in the first quarter of 2025, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics.
• Early data from the Phase I trial, including pain evaluation metrics, is expected by the second quarter of 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful completion of preclinical safety studies with no adverse findings, which is a significant milestone for the company. The clear timeline for IND submission and Phase I trials further supports a positive outlook.

Positives

• The successful completion of the preclinical safety program for Ketamir-2 is a significant milestone.
• No adverse effects were observed in cardiovascular, CNS, and respiratory systems during testing.
• Ketamir-2 was well-tolerated in toxicology studies at high doses.
• The non-mutagenic nature of Ketamir-2 was confirmed.
• The company is on track to submit an IND application by the end of 2024.
• Phase I clinical trials are scheduled to begin in the first quarter of 2025.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The timing of preclinical studies and the filing of the IND for Ketamir-2 are subject to change.
• The success of the Phase I clinical trials is not guaranteed.

Future Outlook

The company plans to initiate Phase I clinical trials in the first quarter of 2025, with early data expected by the second quarter of 2025. The focus will be on safety, tolerability, pharmacokinetics, and pharmacodynamics, as well as pain evaluation metrics to assess Ketamir-2's potential in treating neuropathic pain and psychosis.

Management Comments

• MIRA Pharmaceuticals announced the successful completion of its current Good Laboratory Practice (GLP) preclinical safety program for Ketamir-2.
• The results of these studies demonstrated no adverse findings, clearing a significant milestone toward the submission of the Company's Investigational New Drug (IND) application by the end of 2024.

Industry Context

This announcement is significant for the pharmaceutical industry as it represents progress in the development of a novel oral ketamine analog, which could potentially address unmet needs in the treatment of neuropathic pain and psychosis. The successful completion of preclinical safety studies is a crucial step in bringing new drugs to market.

Comparison to Industry Standards

• The successful completion of GLP preclinical safety studies with no adverse findings is consistent with industry standards for drug development.
• The planned timeline for IND submission and Phase I clinical trials is typical for pharmaceutical companies at this stage of development.
• The focus on safety, tolerability, pharmacokinetics, and pharmacodynamics in Phase I trials aligns with standard practices in the industry.
• The inclusion of pain evaluation metrics in the Phase I trial is relevant for assessing the potential of Ketamir-2 in treating neuropathic pain.

Stakeholder Impact

• Shareholders will likely view the successful preclinical safety results positively.
• The potential for a new treatment for neuropathic pain and psychosis could benefit patients.
• The company's progress may attract further investment and partnerships.

Next Steps

• The company will submit an Investigational New Drug (IND) application by the end of 2024.
• Phase I clinical trials will be initiated in the first quarter of 2025.
• Early data from the Phase I trial is expected by the second quarter of 2025.

Key Dates

Keywords

Ketamir-2, preclinical safety, IND application, clinical trials, ketamine analog, neuropathic pain, psychosis, MIRA Pharmaceuticals, GLP, toxicology